ClinicalTrials.gg
TerminatedNCT04434209LAPISUpdated Mar 6, 2026

A Study Looking at the Use of Biomarkers to Provide Early Indication of Acute Kidney Injury in Patients With Sepsis (Limiting AKI Progression In Sepsis)

An interventional study of Subject management guided by NephroCheck® test and Standard of Care in Sepsis, Acute Kidney Injury and Septic Shock, sponsored by BioMérieux. Terminated at 12 sites in 4 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-03-06.

Primary conditionShock, SepticRegistry: SepsisReclassifiedWhy we changed it
Registry
Sepsis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Shock, Septic
Why
  1. The study's listed conditions name Shock, Septic, a narrower term within Sepsis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by BioMérieux · Not applicable, Interventional, and Diagnostic

How we know

Why this study was terminated
Highly improbable to reach recruitment objective due to impact of COVID-19 pandemic

From the registry’s dates

  • Primary completion was Feb 2022, 4 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 184 studies in Shock, Septic with a site in France — 45 open to participants now, 50 under way, 7 of them phase 3. Shock, Septic · France.

Enrollment
99th of 105
19 · median 120
Started
2021
with 11 others
No phase
52 of 184
14 open now
Registered
114th of 184
by date

Among the 184 studies in Shock, Septic with a site in France, this one is the 99th largest by enrollment of the 105 interventional ones that give a count, is one of 12 that started in 2021, is one of 52 with no phase, and was the 114th registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

45 of the 184 studies in Shock, Septic with a site in France are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Shock, Septic with a site in France, or all of them as a file.
02

Study summary

Biomarkers that provide an early indicator of kidney stress could be useful in clinical practice to detect silent episodes of acute kidney injury (AKI) or for early identification of subjects at risk of AKI. Two urinary biomarkers have been identified as early indicators of AKI. The NephroCheck® test is a commercially available test that uses these biomarkers, and this study assesses the use of these in reducing negative clinical outcomes for patients with sepsis-associated AKI. The study will enroll subjects diagnosed with sepsis, including septic shock, who will be randomly assigned to either receive NephroCheck®-guided kidney-sparing and fast-tracking interventions; or to receive current Standard of Care assessment and treatment.

NOTE: Participants are no longer being recruited to this study.

03

Conditions studied

  • Sepsis
  • Acute Kidney Injury
  • Septic Shock

Browse trials for

Keywords

  • Sepsis
  • Acute Kidney Injury
  • Kidney damage
  • Septic shock
  • Biomarkers
04

In context

Shock, Septic Reclassified

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

This study's enrollment of 19 is below the median of 78 across 639 interventional studies indexed under Shock, Septic.

Browse Shock, Septic studies →

Lead sponsor

BioMérieux is the lead sponsor of 16 studies on the registry; 1 is open to participants now.

Compared within Shock, Septic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of sepsis or septic shock.
  • Admission to the ICU or planned admission to the ICU with an expected stay of 72 hours or more after enrollment in the same hospital.
  • Expected to have indwelling urinary catheter placed and kept until at least 48 hours after enrollment.
  • Written .

Exclusion criteria

Exclusion Criteria:

  • Women with known pregnancy, prisoners or institutionalized individuals.
  • Previous renal transplant.
  • Stage 2 or 3 Acute Kidney Injury (AKI) at screening.
  • Receiving dialysis (either acute or chronic), or in imminent need of dialysis at enrollment.
  • Estimated (eGFR) \< 45 mL/min/1.73 m2.
  • Known End Stage Renal Disease (ESRD) or history of active nephrotic syndrome within the last 3 months.
  • Known Stage 2-3 AKI within last 2 weeks.
  • Terminally ill (defined as expectation of death within 6 months), has a do not resuscitate order that would restrict protocol-required procedures, or is being admitted only for palliative care.
  • History of solid organ transplant and receiving calcineurin inhibitors.
  • Documented serious allergy (i.e. anaphylaxis) to vancomycin, aminoglycosides, penicillins, or cephalosporins (intravenous or oral).
  • Known current serum total > 4mg/dL.
  • Subjects already included in an observational study can be co-enrolled in LAPIS. Subjects already included in an interventional study may be enrolled with pre-approval of the sponsor according to the following rules:

    1. Co-enrollment in LAPIS will not be allowed with drug and device studies;
    2. Studies may be allowed if AKI or kidney function is not an endpoint with pre-approval of the LAPIS sponsor;
    3. Co-enrollment in LAPIS will not be allowed if co-enrollment is an exclusion criterion in the other study.
  • Subjects with laboratory confirmed COVID-19 infection as the primary reason for hospital admission.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    NephroCheck-guided interventions

    Device: Subject management guided by NephroCheck® test

  • Active comparator
    Standard of Care

    Standard of Care assessment and treatment

    Other: Standard of Care

Interventions

  • DeviceSubject management guided by NephroCheck® test

    NephroCheck® is a device using biomarkers to identify subjects at risk of sepsis-associated acute kidney injury

  • OtherStandard of Care

    Standard of Care patient management

07

What researchers measure

Primary outcomes

  1. Number of deaths, dialysis or progression of AKI

    Measured by composite number of deaths, dialysis or progression of AKI. Dialysis defined as any form of renal replacement therapy (RRT); progression of AKI defined as Stage 0 to 2/3 or Stage 1 to 3.

    Time frame: Enrollment to 72 hours

Secondary outcomes

  1. Number of participants with progression of AKI

    Progression of AKI (Acute Kidney Injury) to Stage 2 or 3 during the time frame. Measured independently.

    Time frame: Enrollment to 48 and 72 hours

  2. Number of deaths

    Number of deaths. Measured independently.

    Time frame: Enrollment to 48 and 72 hours

  3. Number of participants receiving dialysis

    Dialysis defined as any form of renal replacement therapy (RRT). Measured independently.

    Time frame: Enrollment to 48 and 72 hours

  4. Number participants at Stage 2 or 3 AKI

    Defined as highest stage of AKI during the time frame

    Time frame: Enrollment to 72 hours

  5. ICU length of stay

    Time frame: Enrollment to hospital discharge or Day 60, whichever is sooner

08

Study locations

12 sites
  • LSU Health Sciences Center, 1541 Kings Highway
    Shreveport, Louisiana 71130, United States
  • Brigham and Womens Hospital, 75 Francis Street
    Boston, Massachusetts 02115, United States
  • Memorial Sloan Kettering Cancer Center, 1275 York Avenue
    New York, New York 10065, United States
  • AZ Sint-Jan Brugge-Oostende, Intensieve Zorgen, Ruddershove 10
    Bruges, West-Vlaanderen 8000, Belgium
  • Hôpital Erasme, Soins Intensifs, Route de Lennik 808
    Brussels, 1070, Belgium
  • CHU Angers, 4 Rue Larrey
    Angers, Maine-et-Loire 49100, France
  • Centre Hospitalier de Béthune, Service de Réanimation et Surveillance continue, 27 rue Delbecque
    Béthune, Pas-de-Calais 62408, France
  • CHRU Dijon Complexe Du Bocage, Department Infectiologie, 14 rue Gaffarel
    Dijon, 21079, France
  • Hopital Cochin, 27 Rue Du Faubourg Saint Jacques
    Paris, 75679, France
  • University Clinic Heidelberg, Klinik für Anaesthesiologie, Im Neuenheimer Feld 110
    Heidelberg, Baden-Wurttemberg 69120, Germany
  • Universitatsklinikum Leipzig, Klinik und Poliklinik für Anästhesiologie und Intensivtherapie, Liebigstraße 20
    Leipzig, Saxony 04103, Germany
  • Universitatsklinikum Munster, Albert-Schweitzer-Campus 1
    Münster, 48149, Germany
09

References and documents

Publications

  • Molinari L, Heskia F, Peerapornratana S, Ronco C, Guzzi L, Toback S, Birch R, Beyhaghi H, Kwan T, Kampf JP, Yealy DM, Kellum JA; Sapphire and Protocolized Care for Early Septic Shock (ProCESS) Investigators. Limiting Acute Kidney Injury Progression In Sepsis: Study Protocol and Trial Simulation. Crit Care Med. 2021 Oct 1;49(10):1706-1716. doi: 10.1097/CCM.0000000000005061. PubMed 33927121 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Feb 2022, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2020
First posted
Jun 16, 2020
StartActual
Jan 19, 2021
Primary completionActual
Feb 14, 2022
CompletionActual
Feb 14, 2022
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04434209
Lead sponsor
BioMérieux
Responsible party
Sponsor
First posted
Jun 16, 2020
Start date
Jan 19, 2021
Primary completion
Feb 14, 2022
Completion
Feb 14, 2022
Last update
Mar 6, 2026

Study contacts

Hernando Gomez, MD, MPH
principal investigator · Center for Critical Care Nephrology, University of Pittsburgh Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion